NCT03256331 is a Phase 1 clinical trial of BEL-X-HG in Advanced Solid Tumors, sponsored by Belx Bio-Pharmaceutical (Taiwan) Corporation.

Who is sponsoring NCT03256331?

NCT03256331 is sponsored by Belx Bio-Pharmaceutical (Taiwan) Corporation.

What drugs are being tested in NCT03256331?

Interventions in NCT03256331: BEL-X-HG.

What condition does NCT03256331 study?

NCT03256331 studies Advanced Solid Tumors.

Is NCT03256331 still recruiting?

NCT03256331 is currently terminated. Last updated 1 June 2020.

Last reviewed 2020-06-01 · How we verify

NCT03256331

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients

Terminated Phase 1 Last updated 1 June 2020

What this trial tests

Phase 1 trial testing BEL-X-HG in Advanced Solid Tumors in 23 participants. Terminated before completion.

Timeline

21 June 2017

Primary endpoint
30 March 2020

30 March 2020

Quick facts

Lead sponsor	Belx Bio-Pharmaceutical (Taiwan) Corporation
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	21 June 2017
Primary completion	30 March 2020
Estimated completion	30 March 2020
Sites	2 locations across Taiwan

Drugs / interventions tested

BEL-X-HG — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Belx Bio-Pharmaceutical (Taiwan) Corporation — full company profile →

Who can join

20 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, open-label, uncontrolled, multicenter dose escalation and extension study to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate safety / tolerability and preliminary effects of BEL-X-HG in patients with advanced refractory solid tumors. Dose escalation during the study will be made based on dose-limiting toxicity (DLT).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03256331 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Belx Bio-Pharmaceutical (Taiwan) Corporation
Last refreshed: 1 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03256331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing